Pharmacokinetics, tissue distribution and excretion of Vitexin in mice by Wang, Yun-jiao et al.
844 ISSN 0326-2383
KEY WORDS: Excretion, HPLC, Pharmacokinetics, Tissue distribution, Vitexin.
* Author to whom correspondence should be addressed. E-mail: yingxixiang@163.com 
Latin American Journal of Pharmacy
(formerly Acta Farmacéutica Bonaerense)
Lat. Am. J. Pharm. 31 (6): 844-51 (2012)
Regular Article
Received: July 6, 2012
Revised version: July 17, 2012
Accepted: July 18, 2012
Pharmacokinetics, Tissue Distribution
and Excretion of Vitexin in Mice
Yun-jiao WANG 1, Gong-lin QU 2, Wen-jie ZHANG 1, He-fei XUE 1,
Ying-hui CHEN 1, Jing-jing YIN 1, Dong-rui LU 1 & Xi-xiang YING 1*
1 School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, China
2 National Institute for Radiological Protection, China CDC, Beijing 100088, China
SUMMARY. Pharmacokinetics, tissue distribution and excretion of vitexin (VIT) were studied after intra-
venous and oral administration to mice at dose of 10 mg/kg and 30 mg/kg, respectively. A sensitive and
specific HPLC method with internal standard was developed and validated for the pharmacokinetic stud-
ies of VIT. The results showed that VIT was rapidly and widespreadly distributed throughout the whole
body after administration and the oral bioavailability of VIT was 3.91 %. The highest VIT level after in-
travenous dose was obtained in gallbladder, followed by lung, liver and kidney. While, the highest VIT lev-
el after oral dose was observed in gallbladder, followed by intestine, stomach, and spleen. The total cumu-
lative excretion percentage of VIT in 24 h after intravenous and oral administration are 31.83 ± 3.85 %
(22.72 ± 2.23 % in urinary excretion; 9.11 ± 1.69 % in fecal excretion) and 10.77 ± 2.34 % (2.92 ±1.05 % in
urinary excretion; 7.85 ± 1.45 % in fecal excretion), respectively.
